Shares of Gilead Sciences Inc (GILD.O) are trading at ultra cheap levels as investors broadly shed biotech holdings and question what the company could do for an encore after several years of torrid growth.
While biotech and healthcare stocks have underperformed the broader market all year, Gilead stands out for its low forward price-to-earnings ratio, which is widely used by investors to value stocks.
The stock closed at $89.53 on Thursday, having lost more than one-fourth of its value since hitting an all-time high of $123.37 in June.
